Imagine a star pitcher at the heart of a major league team's future, expressing a clear desire to stick around despite swirling rumors of a potential shake-up. That's the fascinating situation with Kodai Senga and the New York Mets as we look toward the 2026 season. But here's where it gets controversial: even though the right-hander has voiced his preference to stay in Queens, the Mets might still opt to trade him this winter. Let's dive into the details and unpack why this decision could reshape the team—and spark heated debates among fans.
According to a report from Will Sammon of The Athletic, Mets right-hander Kodai Senga has let the club know he'd rather continue pitching in New York next year instead of being sent off to another team. To clarify for those new to baseball lingo, a right-hander is a pitcher who throws with their right arm, and Senga's preference comes with some nuance due to his contract. He has a ten-team no-trade clause, which means he can block trades to up to 10 specific teams, giving him some control over his destination but not a full veto on all possibilities.
This news stands out because Senga, who turns 33 in January, has been openly discussed as a potential trade piece by the Mets. They've signaled they're open to offers, and rival teams have shown interest, especially since the pool of free agent starting pitchers this year isn't generating much excitement. Some clubs see Senga as a 'buy-low' opportunity—a chance to acquire a valuable player at a bargain price. And his appeal is hard to ignore: Over three seasons in the majors, he's posted a solid career 3.00 ERA (Earned Run Average, a key stat measuring how many runs he allows per game on average) and a 3.82 FIP (Fielding Independent Pitching, which focuses on strikeouts, walks, and home runs he gives up, helping to assess his true skill). Just last season, he delivered a 3.02 ERA in 22 starts for the Mets, which is strong performance for a starter.
For beginners, think of ERA as a report card on a pitcher's ability to prevent hits and runs—lower is better. It's impressive that Senga achieves this at an affordable cost: he'll earn just $28 million over the next two years, with a club option (a decision by the team to extend his contract) for 2028 at a reasonable price. Compare that to last year's free agent market, where one-year deals for veterans like Alex Cobb and Charlie Morton, who had health or age concerns, went for $15 million each. Senga represents a rare find: a potential ace (top-tier starter) on a budget. Teams are lining up for such deals, as high-quality, cost-effective talent doesn't come around often.
Of course, it's not all smooth sailing—there are layers of complexity here that make this story even more intriguing. The Mets themselves are hunting for a front-of-the-rotation star, so why consider trading Senga? Despite his talent and productivity, he's been plagued by reliability issues in New York. Across three big-league seasons, he's only made 52 starts, missing nearly all of 2024 due to shoulder and calf injuries. In 2025, a hamstring strain sidelined him for a month, and upon his return, he struggled with a 5.90 ERA in nine starts before being sent to Triple-A (the minor league level just below the majors) for the rest of the season in early September.
And this is the part most people miss: The Mets benched him entirely from the rotation during a critical playoff push, indicating a lack of faith in his ability to perform consistently. Mets president of baseball operations David Stearns even called it 'foolish' to rely on Senga for a full schedule going into 2025. As he enters his mid-30s, his injury and inconsistency problems might worsen rather than improve, leading some to argue that the Mets' rotation—deep in options but short on dependable stars—would be better served by a more reliable free agent or trade acquisition. It's a counterpoint that could fuel debates: Is Senga's potential worth the risk, or should the Mets prioritize stability?
The Mets have already shown they're willing to make bold moves this offseason, trading longtime Met Brandon Nimmo for Marcus Semien, and other staples like Jeff McNeil are rumored to be on the block. After a disappointing 2025 season, the clubhouse is set for major changes. Whether Senga stays or goes might hinge on his no-trade list, which hasn't been made public. If the Mets push for a trade, they could likely do so with one of the 20 teams not on his approved list.
But things aren't that straightforward. Senga's market value and upside could make the Mets think twice about dealing him for a mediocre return. It's possible the teams most eager to acquire him are exactly the ones he can block, creating a potential roadblock. While his preference to stay in New York doesn't rule out a trade, it certainly complicates the Mets' options and keeps fans on the edge.
If Senga does remain in Queens, the Mets could still bolster their rotation. Prospects and veterans like Nolan McLean (a top young talent with strong 2025 results), Clay Holmes, Sean Manaea, and David Peterson would join him. McLean, with options left (minor league time he can be sent down), is likely a fixture. Manaea, Peterson, and Holmes, who can't be optioned to the minors due to their experience, have bullpen backgrounds for added flexibility. Trading one of them could be an alternative, though none might fetch as much as Senga—and Manaea's high salary and rough 2025 season could make him tough to move.
What do you think, fans? Should the Mets honor Senga's wish and keep him, betting on his potential, or trade him for fresh talent to rebuild stronger? Is sticking with injury-prone players like Senga a smart long-term strategy, or does it scream 'foolish' risk-taking? Share your take in the comments—do you agree with Stearns' cautious view, or are you rooting for Senga to prove the doubters wrong?
